Trastuzumab Regimen Extends PFS in Rare Endometrial Cancer

Adding trastuzumab to chemotherapy increased progression-free survival for patients with advanced HER2/neu-positive uterine serous carcinoma,

Read full article (External website)

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply